Ardelyx CEO’s 10b5‑1 Trades Show Confidence: Buying Low, Selling High
Ardelyx CEO Michael Raab’s latest 10b5‑1 trades show disciplined buying at $0.99 and selling near $5, confirming long‑term confidence amid volatility.
3 minutes to read
Health Care
Arcutis Biotherapeutics: Insider Buy Signals Strategic Growth & Board Expansion
Arcutis Biotherapeutics sees strategic shift with Christopher Peetz’s board appointment and insider buying, hinting at accelerated product launches and Q2 earnings impact.
3 minutes to read
CEO Insider Sale at Monte Rosa: What It Means for Future Oncology Pipelines
CEO sells shares at market peak while Monte Rosa Therapeutics advances oncology & rare‑disease drugs—key insider moves and upcoming FDA approvals could reshape investor outlook.
5 minutes to read
NUVALENT’s $124‑Per‑Share Merger with GSK: Full Insider Sell‑Off and Pipeline Integration
NUVALENT’s merger with GSK ends the company, cashing insiders $124/share, and integrates its oncology pipeline into GSK’s global platform, speeding new therapies.
3 minutes to read
Elevance Health Insider Buying Signals Long‑Term Confidence & AI‑Driven Growth
Elevance Health insider buys 1,000 shares—signaling long‑term confidence in AI‑driven cost control, reimbursement upgrades and a potential upside for investors.
3 minutes to read
CEO Gail Boudraux Buys More Elevance Shares, Signals Undervalued Outlook
Elevance Health CEO’s fresh insider buys show confidence in AI‑driven cost‑control, suggesting stock may rebound after a recent 11% drop.
3 minutes to read
CEO Share Sales at AQUESTIVE Reveal Strategic Liquidity, Not Crisis – What Investors Should Watch
Insightful AQUESTIVE insider trading analysis: how CEO Daniel Barber’s routine liquidity moves reveal confidence, market shifts, and biotech strategy.
4 minutes to read
Greenland Mines CFO Jeff LeBlanc Buys 1.4 Million Shares, Signals Bullish Confidence
Greenland Mines CFO Jeff LeBlanc buys 1.4 M shares at $0.18, signaling confidence in the Skaergaard palladium project and potential upside for cautious investors.
3 minutes to read
Insider Options Surge as Gain Therapeutics Prepares Phase 2 Launch
Insider option grants at Gain Therapeutics signal confidence in its allosteric platform and upcoming Phase 2 trials for systemic sclerosis.
5 minutes to read
Butterfly Network Insider Sale: What It Means for Investors and AI‑Powered Ultrasound Growth
Butterfly Network insider sale: 1.4M shares sold at $7.72, showing no major impact on stock. Learn how this move affects investors, revenue growth, and AI‑driven ultrasound tech.
4 minutes to read